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Clinical trials are increasingly using sensors embedded in wearable de-
vices due to their capabilities to generate real-world data. These devices
are able to continuously monitor, record, and store physiological met-
rics in response to a given therapy, which is contributing to a redesign
of clinical trials around the world. Traditional clinical trials are im-
mensely expensive and limited in testing options, as they typically entail
research participants coming to designated sites for measuring re-
sponses to an investigational treatment. This process creates a costly,
time-intensive pathway from discovery to market and may not produce
results that future patients wish to know, particularly around improve-
ments in activities of daily living and overall quality of life. While wear-
able devices present potential benefits, including a reduction in expense
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and time for researchers as well as burden on research participants,
there are data protection concerns around the magnitude of data that is
generated by these devices. Participants may not be aware of the de-
tailed, granular-level of data being collected from them, and researchers
may be in violation of collecting ‘unintended data’—that is, when the
data collected does not pertain to the original research purpose. These
seemingly opposing views, from individual data protection to sharing
big data across populations as a common resource, would benefit from
drawing on lessons learned in open science. Both data protection regu-
lation and open science emphasize the need for transparency, access to
data, security, and accountability. This Article focuses on the evolving
role for research participants as they become increasingly engaged in
clinical trials through participant-driven data collection, and how data
protection regulation could further empower participants in the re-
search process.
INTRODUCTION
Lawmakers in the European Union and California have enhanced
protection of personal data with the passage of the General Data Pro-
tection Regulation (GDPR)1 and the California Consumer Privacy
Act (CCPA).2 These laws coincide with an evolution in thinking about
open access to data and the role of regulators in sharing data that
could advance science and improve public health. An emerging issue
between privacy concerns and the public interest is individual partici-
pant data and how clinical trials are increasingly collecting data di-
rectly from participants through mobile technologies, wearables, and
other digital health devices. This shift to participant-driven data col-
lection and acceptance of the real-word data they generate in clinical
trials is encouraged by the 21st Century Cures Act,3 with the expecta-
tion that they will accelerate the drug discovery and development pro-
cess. This promise and ability to provide millions of data points on a
wide-range of physiological functions is transforming research design
and creating an unprecedented amount of continuous health monitor-
ing data. The Food and Drug Administration (FDA) flagged the in-
creased risk to privacy with this new technology but has yet to offer
clear guidance.4 Similarly, it is uncertain as to how the newly granted
participants’ rights over personal data under the GDPR and CCPA
1. Commission Regulation 2016/679 of April 27, 2016, General Data Protection Regulation
O.J. (L 119) 1.
2. CAL. CIV. CODE § 1798 (West 2020).
3. 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (Dec. 13, 2016).
4. The FDA has not issued any formal guidance on the 21st Century Cures Act but has pro-
vided general information on the Act. See FDA.GOV, 21st Century Cures Act, https://www.fda
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will be interpreted in a research setting. This developing technological
and legal landscape holds serious implications for health research
around the globe.
Clinical trials provide great benefits to society, for drug develop-
ment, and to research participants. They produce extensive informa-
tion about the safety and effectiveness of drugs and other medical
products to advance scientific discovery,5 and they create access to
investigational therapies not yet on the market. As clinical trials in-
creasingly adopt wearable devices, which have the ability to generate
a magnitude of personal health data previously unimaginable, the pro-
tection of participants’ rights over their data becomes a growing issue
of concern. The benefits of responsibly sharing this wealth of data
through data repositories, and ultimately in an open science informa-
tion commons, further present an opportunity of unrealized potential
as well as raise privacy concerns as de-identifying data becomes less
viable.6
The overarching idea of the open science movement is that scien-
tific knowledge should be publicly available.7 In fact, many institu-
tions that support this idea have adopted the word “commons” to
describe this big data initiative of using health, medical, and genomic
data across populations as a shared resource.8 In addition, some schol-
ars note the ethical and pragmatic importance of a participant-centric
information commons, where efforts are made to empower partici-
pants in the research process by engaging them in a continuous deci-
sion-making role over use of their data.9 Specifically, in a study led by
Amy L. McGuire, the authors identified four critical attributes to sup-
port a participant-centric medical information commons (MIC) that
align well with recent data protection regulations namely the GDPR
and CCPA.10 They are: transparency, access to data, security, and
accountability.11
There are notable variations between the GDPR and CCPA, but
both call for greater transparency and accountability from data con-
.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act (last updated
Mar. 29, 2018).
5. See, e.g., Michelle Mello et al., Clinical Trial Participants’ Views on the Risks and Benefits of
Data Sharing, 378 N.E. J. MED. 2202, 2203 (2018).
6. Id. at 2203.
7. See Mark Phillips & Bartha M. Knoppers, Whose Commons? Data Protection as a Legal
Limit of Open Science, 47 J. L., MED. & ETHICS 106, 107 (2019).
8. Id.
9. See, e.g., Amy L. McGuire et al., Importance of Participant-Centricity and Trust for a Sus-
tainable Medical Information Commons, 47 J. L., MED. & ETHICS, 12, 13 (2019).
10. Id. at 17.
11. Id.
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trollers (natural or legal persons, public authorities, agencies, or other
bodies that process data related to a person) to improve the security
of data and enhance individual rights over personal data.12 The
GDPR and CCPA curtail some of these individual rights if the data
controller claims a research purpose for processing the data.13 They
also vary on which entities are covered, the definition of research,
consent processes, safeguards to protect data, and sanctions. These
variations create predictability problems for researchers conducting
multi-site transnational clinical trials, as well as potential privacy risks
for research participants in simply not knowing or fully understanding
what they may be consenting to when they enter a clinical trial de-
pending on their residency status (i.e., whether they are European
Union residents, California residents, or residents of another country
or U.S. state).14
These data protection efforts and others that are emerging in the
United States and abroad, could benefit from incorporating strategies
used in a participant-centric MIC, such as a dynamic consent process
where participants and researchers have ongoing communication and
enabling participant access to individual-level data. These strategies
bring into harmony the goals of open science and data protection to
promote free movement of personal data so long as there are efforts
to secure data and recognize participants’ rights.15 Additional benefits
with a participant-centric MIC approach include cultivating trust
among research participants in the context of big data.16 A system that
emphasized trust could support diverse recruitment, better retention
in clinical trials, and greater openness towards secondary use of per-
sonal data.
This Article is organized into four parts. Part I describes the bene-
fits and privacy risks related to the use of wearable devices in clinical
trials. Part II provides background information on GDPR and CCPA,
and discusses their influence on state data privacy laws. Part III in-
cludes an analysis of participants’ rights in relation to the research
12. See Phillips & Knoppers, supra note 7, at 107.
13. See Commission Regulation 2016/679, art. 89(2), 2016 O.J. (L119) 1, 84–85 (EU). The
GDPR claims that there must be exemptions to some participants’ rights in order to fulfil the
purposes of scientific research. See CAL. CIV. CODE § 1798.105(d)(6) (West 2020). “Engage in
public or peer-reviewed scientific, historical, or statistical research . . . deletion of the informa-
tion is likely to render impossible or seriously impair the achievement of such research.” Id.
14. The GDPR attempted to harmonize member states for greater consistency with data pro-
tection, but, under Article 9, member states are allowed flexibility to introduce further restric-
tions in the processing of sensitive data, such as health, biometric, and genetic data. Commission
Regulation 2016/697, art. 9, 2016 O.J. (L119) 1, 38–39 (EU).
15. See Phillips & Knoppers, supra note 7, at 110.
16. See McGuire et al., supra note 9, at 17.
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exemption under the GDPR and CCPA. Part IV proposes recommen-
dations from the open science movement, specifically a participant-
centric MIC to better align individual data protections with research
participant engagement.17
I. REAL-WORLD EVIDENCE AND WEARABLES IN CLINICAL TRIALS
Wearables are not new, but the introduction of commercial grade
devices to clinical trials is a recent innovation that is starting to
emerge.18 Wearables have been rising in popularity around the world
since 2006.19 Estimates predict another surge in the next few years,
which expect the wearable market to double to $27 billion market by
2022.20 This growth reflects an increase in the general public’s moni-
toring of overall health and wellness, as well as in research.
Wearables are defined as a small electronic device containing one or
more sensors that are integrated into clothing or other accessories that
can be worn on the body, such as on a wristband, belt, headband, ad-
hesive patch, contact lens, or glasses. 21 Typical consumer-grade, activ-
ity-tracking wearables, such as the Apple Watch or Garmin Viovofit,
come with a three-axis accelerometer to track movement in every di-
rection and many have additional sensors, such as a gyroscope to mea-
sure orientation as well as an altimeter to determine feet hiked or
stairs climbed.22 These consumer-grade wearables can also be used to
collect other biometric measures such as sleep, temperature, and heart
rate.23
The more sensors a wearable has, the more accurate raw data it
collects. Raw data is inputted into the device’s algorithm and trans-
17. See Global Open Access Portal: Open Science Movement, UNESCO.ORG (2017), http://
www.unesco.org/new/en/communication-and-information/portals-and-platforms/goap/open-sci
ence-movement/.
18. See Bill Byrom et al., Selection of and Evidentiary Considerations for Wearable Devices
and Their Measurements for Use in Regulatory Decision Making: Recommendations from the
ePRO Consortium, 21 VALUE IN HEALTH 6, 631–39 (2018). The authors discuss the potential of
wearables to collect rich data and provide valuable insights, yet there is limited guidance on the
acceptability of wearables in the clinical trials. Wearables are grouped into four categories from
external (e.g., 3D camera monitoring movement), worn (devices worn on clothing or on body),
implantable (inserted into body), and ingestible (swallowed by the user).
19. See Amy Westervelt, Wearable Tech Helps You Live in the Moment, SCI. AM. (May 29,
2014), https://www.scientificamerican.com/article/wearable-tech-helps-you-live-in-the-moment.
20. See Paul Lamkin, Smart Wearables Market to Double By 2022: $27 Billion Industry Fore-
cast, FORBES (Oct. 23, 2018) https://www.forbes.com/sites/paullamkin/2018/10/23/smart-wear
ables-market-to-double-by-2022-27-billion-industry-forecast/#3583a50c2656.
21. See Byrom et al., supra note 18, at 631.
22. Caroline Saunders, Balancing Innovation and Regulation: Why the FDA should adopt a
More Dynamic Risk-Based System for Wearables, 58 JURIMETRICS 83, 91 (2017).
23. See id.
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lated into user-friendly statistics on the device. Data stored on the
wearables can be uploaded using a Bluetooth connection to a mobile
device, such as smartphones, tablets, or laptops and then is transmit-
ted to a server that holds a larger data set that is part of the clinical
trial. “Data may be collected in real time, scheduled intervals, or be
proximity-based.”24 Wearables in clinical trials range from consumer
devices—to clinical grade wearables—such as those developed by
Empatica—that are able to measure more specific health conditions,
including the onset of a seizure.25
Currently, about fifteen percent of clinical trials incorporate weara-
ble devices, but in a study conducted by Intel, Kaiser Associates esti-
mates that by 2025 seventy percent of clinical trials will incorporate
this type of sensor technology.26 Wearables can support the collection
of real-world data, which the 21st Century Cures Act defines as “data
regarding the usage, or the potential benefits or risks, of a drug de-
rived from sources other than traditional clinical trials.”27 A recent
study on the increasing adoption of wearables in clinical trials empha-
sized how real-world data collected from wearables can directly ad-
dress limitations in traditionally designed clinical studies.28
Specifically, there are fewer in-person tests, which reduces not only
time and costs, but also the burden on research participants. The study
stated:
While, in the past, more measurements would have directly in-
creased the burden [on research participants], the use of wearable
medical devices can be worn for a prolonged period [and] offer data
without the need for the subject to be bothered over and over
again.29
Clinical trials are typically designed to focus on a reduction of
symptoms, rather than to measure whether the drug or device makes
the participant’s life more liveable.30 For example, a common test in a
clinical trial is a walking test from one point to another over a set
distance. In contrast, measures in a natural environment tracked by
wearables can report walking, stair climbing, and other daily move-
24. Christophe Mombers, Kathleen Legako & Annette Gilchrist, Identifying Medical
Wearables and Sensor Technologies that Deliver Data on Clinical Endpoints, 81 BR. J. CLIN.
PHARMACOL. 196, 197 (2015).
25. See, e.g., id. at 196. For example, a company called Empatica develops wearables to moni-
tor seizures, which can help manage Epilepsy and other medical conditions.
26. See Denise Myshko, Wearables in Clinical Trials, PHARMAVOICE (Mar. 2019), https://
www.pharmavoice.com/article/2019-03-wearables/.
27. See 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (Dec. 13, 2016).
28. See Mombers, Legako & Gilchrist, supra note 24, at 198.
29. Id. at 198.
30. Id. at 196.
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ments over a twenty-four-hour window for a long period of time,
stretching over weeks or months. This form of data provides research-
ers and the participants with practical information (e.g., how is the
participant’s performance with ‘x’ activity at different times of the day
compared over days and weeks?). This type of real-world data col-
lected from wearables can be analyzed to produce real-world evidence
and be used to provide insights into how the treatment is effecting
participants’ activities of daily living and, ultimately, their quality of
life.
The FDA and others have acknowledged a gap between traditional
clinical trials and the evidence needed to support a drug’s optimal use
in a natural, real-world environment.31 Clinical trials, as they are tradi-
tionally designed, suffer from major shortcomings including length of
time, expense, and high failure rate.32 National Institutes of Health
Director, Francis Collins, summarized the poor performance as the
average length of time takes thirteen years from target discovery to
regulatory approval, the failure rate exceeds ninety-five percent, and
the cost per successful drug is over $1 billion, after adjusting for previ-
ous failures.33 Furthermore, their design and protocol may artificially
inflate treatment adherence with research staff and coordination that
is heavily involved in the delivery of care.34
Given the high-cost and low success rate present in clinical trials
and the advantages available with wearable technology, it is not sur-
prising that the Clinical Trials Transformation Initiative (CTTI) issued
a report in 2018. The report strongly endorsed the use of wearables in
clinical trials.35 CTTI is a patient-centered public-partnership whose
primary aim is “to develop and drive adoption of practices that will
increase the quality and efficiency of clinical trials.”36 In the 2018 re-
port, CTTI highlighted the abilities of wearables to reduce barriers to
31. See generally Mombers, Legako & Gilchrist, supra note 24, at 196.
32. Francis S. Collins, Reengineering Translational Science: The Time is Right, 3 SCI. TRANSL.
MED. 90, 1 (2011).
33. See, e.g., Elizabeth Hall-Lipsy, Leila Barraza & Christopher Robertson, Practice-Based
Research Networks and The Mandate for Real-World Evidence, 44 AM. J. L. & MED. 219, 221
(2018).
34. Id.
35. CTTI Recommendations: Advancing the Use of Mobile Technologies for Data Capture &
Improved Clinical Trials, CLINICAL TRIALS TRANSFORMATION INITIATIVE (CTTI) (2018), https://
www.ctti-clinicaltrials.org/files/mobile-devices-recommendations.pdf [hereinafter CTTI 2018].
36. Clinical Trials Transformation Initiative, Strategic Plan, CLINICAL TRIALS TRANSFORMA-
TION INITIATIVE (CTTI) (May 2016), https://www.ctti-clinicaltrials.org/who-we-are/strategic-
plan.
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clinical trial recruitment, lower costs, and increase research partici-
pant engagement.37
The science behind wearables continues to advance due to the pop-
ular demand for public use and use in clinical research.38 For example,
a growing range of physiological functions, including brain activity,
muscle tension, hydration levels, blood pressure, temperature, stress,
and blood chemistry can be regularly collected and stored.39 Data
from wearables also contains physical information about each re-
search participant, including their exact location with dates and time
stamps. If taken together, then this data could be used to reach con-
clusions about a research participants’ whereabouts on any given day
and time as well as physical and emotional states. Vice President of
Clinical Data at Veeva, Richard Young, sums up the data progression:
“Ten years ago, there were a million data points in a big Phase III
study . . . . Today, we are talking about collecting millions of data
points per patient per day.”40
The data collected from wearables offers an abundance of informa-
tion that may go beyond, or be unrelated to, the data needed in a
particular study for which it is being collected and processed. This is
where unintended data issues surface as well related privacy concerns.
Essentially, unintended data is personal data that may not be relevant
to a stated research purpose and is collected by virtue of the transmis-
sion process. The regular uploading of personal data that includes
continuous health monitoring over extended periods of time may pro-
vide more depth and detail than research participants may be aware of
or would have consented to and presents privacy risks that are in need
of further examination. Some privacy advocates claim access to this
kind of unintended data violates notions of fairness and integrity in
the scientific process; and refer to this access as “the biggest civil
rights issue of our time.”41
The privacy concerns regarding the use of wearables in clinical trials
are echoed in data sharing. Some privacy scholars fear that even with
pseudonymization, anonymization, and other protective measures
37. See CTTI 2018, supra note 35.
38. Paul Lamkin, Smart Wearables Market to Double By 2022: $27 Billion Industry Forecast,
FORBES (Oct. 23, 2018), https://www.forbes.com/sites/paullamkin/2018/10/23/smart-wearables-
market-to-double-by-2022-27-billion-industry-forecast/#3583a50c2656.
39. See McGuire et al., supra note 9.
40. See Myshko, supra note 26 (emphasis added).
41. Omer Tene & Jules Polonetsky, Beyond IRBs: Ethical Guidelines for Data Research, 72
WASH. & LEE L. REV. 458, 459 (2016) (citing Alistair Croll, Big Data is Our Generation’s Civil
Rights Issue, and We Don’t Know It, O’REILLY RADAR (Aug. 2, 2012), http://radar.oreilly.com/
2012/08/big-data-is-our-generations-civil-rights-issue-and-we-dont-know-it.html).
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used to de-identify personal data, there may still be a risk to re-iden-
tify individuals, which could have a chilling effect on participation in
clinical trials.42 International organizations, such as the Biometrics In-
stitute,43 are finding privacy concerns lead to a similar reluctance with
wearable use and suggest global standards and guidelines for
wearables that support responsible and ethical use of personal data.44
In a survey presented at a recent Biometrics Institute Conference, sev-
enty-nine percent of participants indicated that privacy concerns were
the most significant roadblock for wider adoption of wearable
technology.45
Wearable use in clinical trials is projected to dramatically increase
over the upcoming years.46 The potential advantages to reduce barri-
ers, lower costs, and accelerate the regulatory approval process could
offer substantial public health benefits.47 In addition, wearables play a
key role in enabling large-scale, participant-driven data collection
where research participants are responsible for reporting data through
their personal devices. This shift in clinical trial design could expand
research participant engagement in several ways, ranging from overall
quality improvement to patient safety.
The utilization of wearable technology incorporates feedback for in-
dividual preferences, their physical reactions and satisfaction levels
with the treatment over time and with certain daily activities (e.g.,
climbing stairs, walking, and sleeping).48 This type of feedback model
aligns with the concept of continuous quality improvement—system-
atically measuring and iteratively improving customer or patient satis-
faction—in which quality improvement is defined and measured from
the patient perspective.49 In a clinical trial, collection of dense physio-
42. See Mello et al., supra note 5, at 2203; GDPR Article 4 defines pseudonymization as “the
processing of personal data in such a manner that the personal data can no longer be attributed
to a specific data subject without the use of additional information.” Commission Regulation
2016/697, art. 4, 2016 O.J. (L119) 1, 33 (EU).
43. Biometrics Institute, https://www.biometricsinstitute.org/ (last visited Jan. 22, 2020).
44. See, e.g., Chris Burt, Biometrics Institute Announces Initiatives to Support Ethical and Re-
sponsible Biometrics Use, BIOMETRIC UPDATE.COM (Jan. 29, 2019), https://www.biometricupdate
.com/201901/biometrics-institute-announces-initiatives-to-support-ethical-and-responsible-bio
metrics-use.
45. See Unisys Corporation, Unisys Survey Finds Wearable Technology to Revolutionize Bio-
metrics; Privacy Issues Yet to Be Addressed, PR NEWSWIRE (Aug. 23, 2016), https://www.prnews
wire.com/news-releases/unisys-survey-finds-wearable-technology-to-revolutionize-biometrics-pri
vacy-issues-yet-to-be-addressed-300316454.html.
46. See generally Myshko, supra note 26.
47. See CTTI 2018, supra note 35.
48. See generally Byrom et al., supra note 18.
49. See, e.g., Eleanor D. Kinney et. al., Quality Improvement in Community-Based, Long-
Term Care: Theory and Reality, 20 AM. J. L. & MED. 59, 73 (1994); see also Rachel Zuraw &
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logical data may identify early safety issues, as well as inform dose
adjustments and frequencies.50 Research participants could add their
voice to the data collected by wearables and help identify potential
safety issues and dosing preferences; even difficulties with medication
adherence could support safety goals and participants’ retention in the
clinical trial.
There are benefits associated with the use of wearables in clinical
trials that could greatly improve the traditional clinical trial design
from producing real-world data, reducing costs, and supporting
greater engagement with research participants. However, these bene-
fits need to be considered in conjunction with the ability of wearables
to generate vast amounts of unintended data that research partici-
pants may not be aware they are providing. Given the escalating use
of wearables in clinical trials and rapidly developing sensor capabili-
ties that will increasingly be able to collect a greater granularity in
physiological functions, there are privacy risks that should be urgently
addressed in the evolving regulations, namely GDPR and CCPA.
II. DATA PROTECTION RIGHTS
The GDPR and CCPA reflect a worldwide trend towards greater
accountability to protect personal data, while simultaneously balanc-
ing support for research and the responsible sharing of clinical data.
The GDPR, which went into effect in May of 2018, is working to rec-
oncile these goals and resolve uncertainty with further guidance from
the European Commission and other agencies.51 The CCPA took ef-
fect in January of 2020, solely for California residents, but continues to
be considered by other states and federally for future regulation.52
The advances in wearables and other sensor technologies could fur-
ther impact current and future data protection regulations in ways not
fully fathomed. All these factors suggest that there is an opportunity
to refine how the GDPR, CCPA, and other data privacy laws regulate
research so that it is compatible with the goals of research participant
engagement and open science.
The GDPR and CCPA define personal data and participants’ rights
to processing of personal data with notable differences. The GDPR
Tara Sklar, Digital Health Privacy and Age: Quality and Safety Improvement in Long-Term
Care, IND. HEALTH L. REV. (forthcoming 2020).
50. See Elena S. Izmailova et al., Wearable Devices in Clinical Trials: Hype and Hypothesis,
104 CLIN. PHARMACOL. THER. 42, 43 (2018).
51. Commission Regulation 2016/679 of April 27, 2016, General Data Protection Regulation
O.J. (L 119) 1.
52. CAL. CIV. CODE § 1798 (West 2020).
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considers personal data as “any information relating to an identified
or identifiable natural person, directly or indirectly.”53 This can en-
compass addresses, license plate numbers, social security numbers,
blood type, bank account information, and a person’s online identifi-
ers, such as Internet Protocol addresses as well as one or more factors
specific to the physical, physiological, genetic, mental, economic, cul-
tural, or social identity of that natural person.54 The CCPA defines
personal data as “any information that identifies, relates to, describes,
is capable of being associated with, or could reasonably be linked di-
rectly or indirectly, with a particular consumer or household.”55 Both
the GDPR and the CCPA are concerned with protecting information
that could be directly or indirectly linked to identify a natural
person.56
A. General Data Protection Regulation
The GDPR was passed by the European Union in 2016 and went
into effect in May of 2018 across thirty-one countries, with implica-
tions for any entity that processes data from an EU resident.57 Al-
though the GDPR is an EU regulation, it applies to all organizations
(businesses, non-profits, and government entities) that collect, pro-
cess, or hold data collected from users in the European Union, regard-
less of where the controllers or processors are based.58 Entities are
subject to the GDPR if their activities involve processing of personal
data of an individual located in the European Union, which can range
from a U.S. citizen temporarily in the European Union with a weara-
ble device to multi-site transnational clinical trials, or a data center on
another continent storing data collected from persons in the European
Union.
53. See Commission Regulation 2016/697, art. 4(1), 2016 O.J. (L119) 1, 33 (EU).
54. See id.
55. See CAL. CIV. CODE § 1798.140 (West 2020).
56. See Table 1 for a side-by-side comparison of participants’ rights granted under the GDPR
and CCPA.
57. There are twenty-eight EU member states and thirty-one states that are part of the Euro-
pean Economic Area. There are additional countries that the EU Commission recognizes as
providing an adequate level of data under its “adequacy” status in Article 45 of the GDPR.
Commission Regulation 2016/697, art. 45, 2016 O.J. (L119) 1, 61 (EU). See also European Com-
mission, Adequacy of the Protection of Personal Data in Non-EU Countries, https://ec.europa
.eu/info/law/law-topic/data-protection/data-transfers-outside-eu/adequacy-protection-personal-
data-non-eu-countries_en.
58. See id.
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The GDPR overhauls the ways in which organizations collect, use,
and share personal data.59 In a research setting, the GDPR aims to
support digital technology (including wearables) by reducing barriers
to process personal data for a research purpose, while maintaining
ethical obligations regarding consent and protection of research par-
ticipants. The GDPR also attempts to address “shortcomings” of the
previous EU data privacy law that was passed in 1995, Data Protec-
tion Directive (DPD).60 Examples include the creation of notification
policies for participants and authorities when there is a data breach
and the strengthening of rules for data minimization.61
The GDPR has seven key principles for processing of personal data:
“Lawfulness, fairness and transparency[;] purpose limitation[;] data
minimization[;] accuracy[;] storage limitation[;] integrity and confiden-
tiality (security)[; and] accountability.”62 The principles relating to
purpose limitation and data minimization are the most pertinent to
the question of how to regulate unintended data generated by
wearables in clinical trials. Overall, even if the data collection and
processing is done in a research setting, the GDPR aims for organiza-
tions to limit the scope to: (1) A person’s data may only be collected
for a specific purpose; (2) The person must be informed of and con-
sent to the purpose for which their data is collected; (3) Only as much
data as is necessary to achieve that purpose should be collected; (4)
The collected data must be deleted at the request of the person from
whom it was collected, or when it is no longer needed for the purpose
for which it was collected.63 In short, GDPR asks all organizations to
understand what data they are collecting, why they are collecting it,
and to establish mechanisms to manage that data.
B. California Consumer Privacy Act
The CCPA was signed by Governor Jerry Brown on June 28, 2018
and went into effect on January 1, 2020.64 Although not as extensive in
scope as the GDPR, it is arguably the strongest U.S. consumer privacy
59. See, e.g., Edward S. Dove, The EU General Data Protection Regulation: Implications for
International Scientific Research in the Digital Era, 46 J. L., MED., & ETHICS 1013, 1014 (2018).
60. See Directive 95/46, 1995 O.J. (L 281) 1, 31 (EC).
61. See, e.g., Politou, Eugenia, Efthimios Alepis & Constantinos Patsakis, Forgetting Personal
Data and Revoking Consent Under the GDPR: Challenges and Proposed Solutions, 4 J. OF
CYBERSECURITY 1, 4 (2018).
62. Guide to the General Data Protection Regulation, INFORMATION COMMISSIONER’S OFFICE
https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protec
tion-regulation-gdpr/principles/ (last visited Jan. 22, 2020).
63. See id.
64. CAL. CIV. CODE § 1798 (West 2020).
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law to date and an outcome of the GDPR’s influence. The CCPA pro-
vides California residents with a legal framework to protect their per-
sonal data. Its applicability is limited to large businesses with $25
million or more in gross revenues, processing data of 50,000 consum-
ers, and fifty percent of revenue from data sales.65 The CCPA creates
new rights that make current privacy notices and their more genera-
lized statements obsolete. For instance, under the right to data access,
consumers (i.e., participants) can request from a business the catego-
ries of personal information, and the specific pieces of personal infor-
mation, that the business has collected about the specific consumer.66
The business must then notify consumers of this fact.67 Meanwhile
under the right to deletion, consumers can request that a business de-
lete any of their personal information that the business holds, and the
business’s online privacy notice must include notification of this
right.68
The CCPA also requires, upon receipt of a verifiable consumer re-
quest, that a business collecting personal information about the con-
sumer disclose the following:69
1. Categories of personal information collected about the
consumer.
2. Categories of sources from which personal information is
collected.
3. Business or commercial purposes for collecting or selling the
personal information.
4. Categories of third parties with which the personal information
is shared; and
5. Specific pieces of personal information collected about that
consumer.
65. See § 1798.140(c).
66. See § 1798.100.
67. § 1798.100.
68. § 1798.105.
69. § 1798.115.
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TABLE 1: Participants’ Rights Granted Under the CCPA and GDPR
 CCPA GDPR 
Rights  
Granted 
1. Right to disclosure 
2. Right to deletion 
3. Right to data access 
4. Right to opt-out 
5. Right to non- 
discrimination 
1. Right to be informed 
2. Right to access 
3. Right to rectification 
4. Right to erasure 
5. Right to restrict processing 
6. Right to data portability 
7. Right to object 
8. Rights in relation to  
automated individual  
decision making, profiling 
C. GDPR and CCPA Influence on State Data Privacy Laws
A controversial issue on which the GDPR and CCPA diverge is opt-
out/opt-in consent, and this is also hotly contested in state data privacy
laws. The CCPA uses the right to opt-out, which enables consumers
to, at any time, opt out of a business’s sale of a consumer’s personal
information to third parties.70 Furthermore, any businesses that may
sell personal information to third parties are required to provide no-
tice of potential sale and of a consumer’s right to opt-out.71 The
GDPR mandates an opt-in approach, which means that individuals
must provide affirmative consent for their data to be processed, mean-
ing it must be “freely given, specific, informed and unambiguous.”72
The trend in the United States regarding state data privacy laws fol-
lows the CCPA model and allows individuals to opt-out of certain
uses, namely the selling of their personal data to a third party.73
Critics of the GDPR claim that the opt-in approach would stymie
competition, since consumers might only opt-in to more established
companies’ websites and online services.74 They also doubt whether it
70. CAL. CIV. CODE § 1798.120 (West 2020).
71. § 1798.120.
72. Commission Regulation 2016/697, art. 4(11), 2016 O.J. (L119) 1, 34 (EU). Article seven of
the GDPR further discusses the conditions of consent. See id. at art. 7, 37.
73. CAL. CIV. CODE § 1798.115(d).
74. Caroline Spiezio, Privacy Notices, Opt-In Clauses Debated as US Regulators Shape Federal
Privacy Law, CORPORATE COUNSEL (Mar. 12, 2019), https://www.law.com/corpcounsel/2019/03/
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enhances individuals’ privacy.75 In contrast, advocates for the opt-in
approach note that most people do not adjust the default settings and
have concerns that it is not possible to meaningfully opt-out.76 This
opt-in preference is largely shared by those who support a participant-
centric MIC. Studies show that research participants prefer opt-in
consent, and some experts claim that opt-out consent can be exploita-
tive, erode trust, and come off as sneaky.77
The GDPR and CCPA also sharply diverge on sanctions for non-
compliance. The GDPR provides a tiered approach where organiza-
tions can be fined up to four percent of annual global turnover or C= 20
million, whichever is greater, for breaches of data protection princi-
ples or data participants’ rights.78 An organization can be fined C= 10
million or two percent of annual global turnover, whichever is greater,
for data security breaches, not informing data participants about a
breach, or poor record keeping.79 In contrast, the CCPA fines organi-
zations in breach up to $2,500 per violation for negligent violations
and up to $7,500 per violation for intentional violations.80
This wide disparity in sanctions between the GDPR and CCPA
have implications for an organization’s level of effort to secure data,
and the future direction of state data privacy laws. If sanctions are
minimal, then data security may not receive the resources necessary to
make it a top priority. Related concerns regarding accountability, en-
forcement, and recourse for victims of data misuse or privacy breaches
are all important considerations in refining the GDPR, CCPA, as well
as the current and proposed state data privacy laws.
Interestingly, Senators Amy Klobuchar (D-MN) and Lisa Murkow-
ski (R-AK) recently proposed the Protecting Personal Health Data
Act,81 a bi-partisan federal data privacy law that incorporated princi-
ples directly from the GDPR. Namely, the Bill would allow individu-
als to delete and amend their health data as well as access individual
copies.82 This proposed legislation is particularly notable in the con-
12/privacy-notices-opt-in-clauses-debated-as-us-regulators-shape-federal-privacy-law/?slreturn=
20190230102041.
75. Id.
76. Id.
77. See McGuire et al., supra note 9, at 16.
78. See Dove, supra note 59, at 1013.
79. Id. at 1015.
80. See CAL. CIV. CODE §§ 1798.150, 1798.155(c) (West 2020). The CCPA creates the “Con-
sumer Privacy Fund” within the General Fund of the State Treasury.
81. See Protecting Personal Health Data Act, S. 1842, 116th Cong. (2019), https://www.con
gress.gov/bill/116th-congress/senate-bill/1842?q=%7B%22search%22%3A%5B%22personal+
data+health%22%5D%7D&s=1&r=1.
82. Id.
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text of this Article for its goal to directly address the category of per-
sonal health data collected by wearables and related technologies. If
enacted, Health and Human Services would, in conjunction with other
regulatory stakeholders, promulgate regulations that would
strengthen privacy and security protections for personal health data;
apply uniform standards for consent as well as appropriate exceptions;
include minimum security standards; and require limits on collection,
use, and disclosure of data to only those directly relevant and neces-
sary to accomplish a specific purpose.83 Not surprisingly, California is
considering a similar bill, Information Privacy: Digital Health Feed-
back Systems,84 concerning this type of health data. This proposed leg-
islation would expand California’s health privacy law to include any
information from a digital health feedback system, which is broadly
defined to include sensors, devices, and internet platforms that receive
personal health data.85
III. RESEARCH EXEMPTION AND RELATED SAFEGUARDS
Legislators passed the GDPR and CCPA to strengthen privacy and
data protection, while allowing an exemption for research. They differ
both in how they define research and in how they apply a research
exemption, which allows for some research participants’ rights to be
curtailed—specifically, the rights to erase or delete personal data and
restrict processing.86 For example, organizations may not be required
to comply with participants’ requests to erase their data from the
clinical trial as that right is “likely to render impossible or seriously
impair the achievement of the specific purpose.”87 Retention is a chal-
lenge for clinical trials, in general, and allowing participants to entirely
erase their data could jeopardize the quality of the data and signifi-
cance of the research findings. Researchers may also avoid restrictions
under this exemption and conduct further processing of sensitive cate-
gories of data if they can show a “compatible purpose” with the data
83. Id.
84. Information Privacy: Digital Health Feedback Systems, A.B. 384, Reg. Sess. (Cal. 2019).
85. Id.
86. See GDPR’s art. 17(3)(d) so-called right to be forgotten does not apply if processing is for
research purposes as defined under art. 89(1). Compare Commission Regulation 2016/679, art.
17(3)(d), 2016 O.J. (L119) 1, 44 (EU) with Commission Regulation 2016/679, art. 89, 2016 O.J.
(L119) 1, 84–85 (EU). See also CAL. CIV. CODE § 1798.105 (West 2020).
87. See Commission Regulation 2016/679, art. 89(2), 2016 O.J. (L119) 1, 84–85 (EU). The
GDPR claims that there must be exemptions to some participants’ rights in order to full the
purposes of scientific research. See also CAL. CIV. CODE § 1798.105(d)(6). “Engage in public or
peer-reviewed scientific, historical, or statistical research . . . when the businesses’ deletion of the
information is likely to render impossible or seriously impair the achievement of such research, if
the consumer has provided informed consent.” Id.
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that was initially collected.88 This Part discusses the differences be-
tween the GDPR and CCPA in a research context, including ap-
proaches to consent, exemption, and safeguards for research
participants’ data.
The GDPR offers more flexibility than its predecessor, the DPD, by
providing greater latitude in creating new exemptions for researchers
to process personal data. This broad research exemption reflects its
mandate to facilitate a digital single market across EU member
states.89 As such, the GDPR provides a far-reaching definition of re-
search where it encompasses “technological development and demon-
stration, fundamental research, applied research, and privately funded
research.”90 This results in a wide umbrella of “research” activities
that could be included under the research exemption. The CCPA, by
contrast, has a limited scope in how it defines research. Specifically,
research only refers to federally sponsored research.91 It is unclear if
privately funded research could also claim a research exemption and
override certain participants’ rights.
Since this is an evolving area of determining how to regulate vast
amounts of personal data in clinical trials, it is unclear how to align
participants’ rights with informed consent without placing an undue
burden on researchers, particularly for sponsors that run transnational
clinical trials. Consistent with its aim to promote harmonization across
the European Union, the GDPR attempts to satisfy the ethical obliga-
tion for consent in such a way that it would minimize the burden for
data processing in an international research context.92 The GDPR re-
quires informed consent and that researchers treat participants in a
fair and transparent way by providing information about what their
data will be used for, who will process it, and how it will be stored.93
The CCPA follows the revised Common Rule, which is the Basic
HHS Policy for Protection of Human Research Subjects, which re-
quires broad consent.94 If researchers are able to obtain broad consent
for the storage, maintenance, and secondary research use of identifi-
able biospecimens and data, then any subsequent uses of the individ-
88. Commission Regulation 2016/679, art. 9(2)(j) & 6(4) & Recital 50, 2016 O.J. (L119) 1, 39
& 37 & 9–10 (EU).
89. See Gabe Maldoff, How GDPR Changes the Rules for Research, International Association
of Privacy Professionals, IAPP.ORG (Apr. 19, 2016), https://iapp.org/news/a/how-gdpr-changes-
the-rules-for-research/.
90. See Commission Regulation 2016/679, Recital 159, 2016 O.J. (L119) 1, 30 (EU).
91. CAL. CIV. CODE § 1798.145(c)(1)(C) (West 2020).
92. See Maldoff, supra note 89.
93. See Commission Regulation 2016/679, art. 7, 2016 O.J. (L119) 1, 37 (EU).
94. See 45 C.F.R. § 46.104 (d)(7) (2018).
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ual’s identifiable biospecimens and data consistent with the initial
broad consent would not require additional consent.95 The CCPA de-
fines research in such a narrow way that if an organization meets the
research definition, then it seems straightforward to apply the re-
search exemption. The GDPR is less clear in whether specific or
broad consent is required, even if a research exemption applies.96
The research exemption is subject to safeguards under the GDPR
and CCPA. The GDPR includes several safeguards, with the princi-
ples of data minimization, purpose limitation, and “data protection by
design” as the most applicable to this issue of unintended data largely
collected from wearables.97 The principle of data minimization states
that only data, which is “adequate, relevant, and limited to what is
necessary in relation to purposes for which data is being processed”
should be collected, stored, and used.98 The purpose limitation re-
quires that data should not be processed for any other purpose and
should not be held after the data storage expires.99 This type of data
protection by design requires researchers to put in place “technical
and organizational measures” to ensure that they process only the
personal data necessary for the research purposes.100
The CCPA provides a similar safeguard, which is, “permit access
only to the minimum necessary personal information needed for the
research project.”101 There is a lack of clear guidance in how to recon-
cile the research exemption with its related safeguards when it comes
to unintended data. The implications of this could be whether the re-
search exemption will override participants’ rights for processing un-
intended data, meaning data that may not be necessary for carrying
out the stated research purpose. A further complication for predict-
ability goals is that EU member states can require additional safe-
guards for any exemptions granted for research purposes.102
IV. RESEARCH PARTICIPANTS’ DATA AND OPEN SCIENCE
International collaboration in the research space is supported
through responsibly sharing clinical trial data, which has been critical
95. Id.
96. See Phillips & Knoppers, supra note 7, at 109.
97. Commission Regulation 2016/679, art. 5, 2016 O.J. (L119) 1, 35–36 (EU).
98. See id., art. 5(1)(c), 35.
99. Id., art. 5(1)(b), 35.
100. See id., art. 5, 35–36.
101. See CAL. CIV. CODE § 1798.24(t)(2)(B) (West 2020).
102. See Commission Regulation 2016/679, art. 9(2)(j), 2016 O.J. (L119) 1, 39 (EU).
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to improve drug development and regulatory processes.103 Much em-
phasis has been placed by regulatory agencies on the importance of
data sharing, especially for its ability to shed light on concerns of inac-
curate, biased, and insufficient reports that would be nearly impossi-
ble to resolve without access to underlying trial data.104 Additionally,
scientific discovery could advance with access to this data and poten-
tially identify issues that were missed, understudied, or buried. As
wearables become increasingly used in clinical trials, sharing data
from these devices will become more widespread and could exponen-
tially improve medical knowledge, particularly once challenges
around data translation are addressed.
There are a number of strategies that relate to an open science initi-
ative of responsibly sharing clinical trial data through a participant-
centric MIC and that also align with data protection principles. This
Part describes three strategies that adhere to the goals of the GDPR
and CCPA and have the potential to expand research participant en-
gagement in clinical trials. The strategies are dynamic consent, partici-
pant access to individual-level data, and a robust system of
accountability.
Dynamic consent is not required under the GDPR or CCPA but
could provide some needed clarity as well as support for research and
innovation goals. Dynamic consent is primarily designed to facilitate
two-way, ongoing communication between the researcher and re-
search participant.105 It utilizes a communication platform that allows
researchers to follow up with participants over time, which, given the
real-time capabilities of using wearables in research, could be a tre-
mendous advantage for early identification of potential safety issues
or adjustments for dosing amounts and frequencies. This approach
could improve retention as researchers can be more responsive if par-
ticipants are thinking of dropping out of a trial due to a change in
their condition or adverse response to the treatment. Also, dynamic
consent could alleviate data protection concerns regarding whether
research participants fully comprehend the level of detail and depth
that is collected about them through wearables’ continuous health
monitoring. Lastly, dynamic consent supports follow-up studies where
researchers are more likely to stay in contact with participants that
may have moved locations or reengage them if they have lost interest.
103. See Martha Brumfield, The Critical Path Institute: Transforming Competitors into Collab-
orators, 13 NATURE REVS. DRUG DISCOVERY 785 (2014).
104. Id.
105. See Mary A. Majumder et al., The Role of Participants in a Medical Information Com-
mons, 47 J. L., MED. & ETHICS 51, 53 (2019).
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Access to individual-level data is a feature that can be addressed
during the design process and is also part of the participants’ rights to
personal data protection. In addition, this feature promotes trans-
parency and trust between researchers and research participants, as
well as empowerment for the participant by allowing them to become
more engaged in the research process.106 A robust system of accounta-
bility closely aligns with the goals of data protection—requiring sanc-
tions and outline enforcement mechanisms. There are benefits to
harmonizing an accountability system so that researchers can comply
without conflicting requirements across jurisdictions. Additionally, re-
search participants could understand their rights and redress options
available to them if there is a data breach or misuse of data that is not
dependent on their particular location.
There is tremendous opportunity to inform the evolving GDPR,
CCPA, state data privacy laws, and potential federal data privacy laws
with these types of strategies, which could also expand research par-
ticipant engagement. Incorporating these strategies could address
some of the confusion regarding the safeguards for data protection
under the GDPR. For example, dynamic consent would ensure that
research participants’ preferences and concerns are part of whether
they consider minimal data collection related to the research purpose.
Researchers should consider the ethical and practical benefits in
adopting these types of strategies, which range from better meeting
the needs of those receiving the treatment to complying with data pro-
tection principles and reducing costs associated with attrition.
CONCLUSION
The GDPR and CCPA affirmatively recognize research partici-
pants’ greater control over personal data. However, it is unclear how
these types of data protection regulations will balance privacy with
research, especially in regard to applying the research exemption to
data that arguably does not meet the data minimization safeguards
required under the GDPR and CCPA. The current regulations re-
present a step forward in the global trend to enhance participants’
rights, particularly when there are potential privacy risks with the in-
creasing use of wearables and related technologies. Amendments to
the GDPR, CCPA, and state data privacy laws are actively taking
place, and new data protection regulations are being proposed. Now is
106. See McGuire et al., supra note 9, at 17.
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the time to introduce approaches that align the goals of data protec-
tion with open science and bring a needed level of continuous partici-
pant engagement into the research process.
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